Haemonetics (HAE) Reports Q4 Revenue of $346 Million, Up 5%

Haemonetics (HAE) announced fiscal Q4 revenue of $346 million, reflecting a 5% increase reported and a 9% rise organically excluding CSL, with adjusted EPS at $1.29. For the full year, revenue reached $1.3 billion, and adjusted EPS stood at $4.96. Key growth drivers included Plasma and Blood Management Technologies, with Plasma revenue at $130 million, up 13% organically. Fiscal 2027 guidance anticipates revenue growth between 4% and 7%, alongside adjusted operating margin expansion of 50 to 100 basis points.

Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.